Related Experiment Video
Updated: Jan 27, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy:
Vanessa M Silva1, Maurício Scanavacca2, Francisco Darrieux2
11 Clinical Laboratory Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Insights
Routine coagulation tests like aPTT and PT can help monitor direct oral anticoagulant (DOAC) levels for dabigatran and rivaroxaban. These tests aid in identifying subtherapeutic concentrations, improving patient therapy.
Area of Science:
- Pharmacology
- Clinical Chemistry
- Hematology
Background:
- Direct oral anticoagulants (DOACs) such as dabigatran and rivaroxaban are crucial for managing nonvalvular atrial fibrillation.
- Understanding the impact of DOACs on routine coagulation tests is essential for effective therapeutic monitoring.
- Variability in DOAC levels can affect patient outcomes and requires reliable monitoring methods.
Purpose of the Study:
- To investigate the association between plasma concentrations of dabigatran and rivaroxaban and standard coagulation test results.
- To evaluate the utility of routine coagulation tests in identifying therapeutic and subtherapeutic DOAC levels.
- To establish correlations between specific DOACs and their effects on activated partial thromboplastin time (aPTT) and prothrombin time (PT).
Main Methods:
- Patients with nonvalvular atrial fibrillation on dabigatran (150 mg) or rivaroxaban (20 mg) had blood samples collected 2 hours post-dose.
- DOAC concentrations were measured using specific assays: Hemoclot thrombin inhibitor (HTI) for dabigatran and Anti-Xa-Riva for rivaroxaban.
- Routine coagulation tests, including aPTT and PT, were performed on the collected samples.
Main Results:
- The median dabigatran level was 128.3 ng/mL, with HTI assay showing a strong correlation with aPTT (R² = 0.74, P < .0001).
- The median rivaroxaban level was 223.9 ng/mL; Anti-Xa-Riva correlated with PT (R² = 0.69, P < .0001) and aPTT (R² = 0.36, P < .001).
- Prolonged PT was observed even below the therapeutic range for rivaroxaban, indicating routine tests can detect out-of-range concentrations.
Conclusions:
- Routine coagulation tests, specifically aPTT for dabigatran and PT for rivaroxaban, demonstrate significant correlations with drug levels.
- These screening tests are capable of identifying both supratherapeutic and subtherapeutic concentrations of dabigatran and rivaroxaban.
- The findings support the use of aPTT and PT as valuable tools for monitoring DOAC therapy and ensuring optimal patient management.
Abstract:
Dabigatran and rivaroxaban, direct oral anticoagulants (DOACs), affect coagulation tests, and knowledge of their effects is important for therapeutic monitoring. Our aim was to examine the association between DOAC levels and routine coagulation tests in patients with nonvalvular atrial fibrillation. Samples from patients receiving dabigatran (150 mg) and patients receiving rivaroxaban (20 mg) were collected 2 hours after drug intake. Direct oral anticoagulant concentrations were determined using direct Hemoclot thrombin inhibitor (HTI) assay (HTI test) and a direct Xa inhibitor (Anti Xa-Riva). The routine coagulation measured included activated partial thromboplastin time (aPTT) and prothrombin time (PT). The median plasmatic dabigatran was 128.3 ng/mL (95% confidence interval [CI]: 93.7-222.6 ng/mL). The HTI exhibited a good correlation with aPTT ( R2 = 0.74; P < .0001). The median plasmatic rivaroxaban was 223.9 ng/mL (95% CI: 212.3-238.9 ng/mL). Anti-Xa-Riva correlated with PT ( R2 = 0.69, P< .0001) and aPTT (R2 = 0.36, P < .001), but prolonged PT results were obtained, even below the rivaroxaban therapeutic range (20%). The routine coagulation tests were able to identify out of therapeutic range concentrations for dabigatran and rivaroxaban. We suggest the use of these screening tests to better understand and monitor the subtherapeutic concentrations of these DOACs.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Coagulation
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Reliability and Validity
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...

